Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207
AMES, Iowa , Dec. 23, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company has entered into an exclusive worldwide license agreement with Ellipses Pharma Limited (Ellipses) for the development of and rights to commercialize NLG207 (formerly CRLX101),
View HTML
Toggle Summary NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)
AMES, Iowa , Dec. 20, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that, after priority review, the FDA has granted approval of ERVEBO® , or Zaire Ebola virus vaccine V920 (rVSV∆G-ZEBOV-GP), as confirmed by our partner, Merck (NYSE:MRK), known as MSD outside
View HTML
Toggle Summary NewLink Genetics Responds to Proposal from Evercel
Board Continues to Believe that Planned Lumos Merger Agreement is in the Best Interests of NewLink Stockholders AMES, Iowa , Dec. 16, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink” or the “Company”) today publicly announced its rejection of the unsolicited
View HTML
Toggle Summary NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)
AMES, Iowa , Nov. 12, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11 th , the European Commission (EC) granted a conditional marketing authorization to ERVEBO®, investigational V920 Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP) , as confirmed by our
View HTML
Toggle Summary NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Management to host conference call today at 8:30 a.m. ET AMES, Iowa , Nov. 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update on corporate activities.
View HTML
Toggle Summary NewLink Genetics to Host Its Third Quarter 2019 Conference Call on November 6, 2019
AMES, Iowa , Oct. 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its third quarter 2019 conference call and webcast at 8:30 AM ET on Wednesday, November 6, 2019, to discuss its third quarter financial results and provide an update on corporate
View HTML
Toggle Summary NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)
AMES, Iowa , Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th , the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a conditional marketing
View HTML
Toggle Summary NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases
-- Combined company to assume the name, Lumos Pharma, Inc. and is expected to be led by Richard J. Hawkins , current CEO of Lumos Pharma -- -- Lumos asset, LUM-201, represents first oral therapeutic candidate for pediatric growth hormone deficiency (PGHD) with planned Phase 2b expected to begin in
View HTML
Toggle Summary NewLink Genetics Announces FDA Accepts Partnered Biologics License Application (BLA) and Grants Priority Review for Ebola Vaccine V920 (rVSV∆G-ZEBOV-GP)
AMES, Iowa , Sept. 17, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted Merck’s Biologics License Application (BLA) and granted priority review for the investigational Ebola vaccine (V920), for the
View HTML
Toggle Summary NewLink Genetics Provides Corporate Update and Reports Second Quarter 2019 Financial Results
Announces management transition; Charles J. Link Jr, M.D. to retire as CEO and Chairman of the Board AMES, Iowa , July 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink Genetics” or the “Company”) today announced financial results for the second quarter ended June
View HTML